anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In vitro and in vivo pharmacologic studies have demonstrated that terbutaline exerts a preferential effect on beta2-adrenergic receptors. While it is recognized that beta2-adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta2-receptors in the human heart, existing in a concentration between 10% to 50%. The precise function of these receptors has not been established [see WARNINGS]. In controlled clinical studies in patients given terbutaline sulfate orally, proportionally greater changes occurred in pulmonary function parameters than in heart rate or blood pressure. While this suggests a relative preference for the beta2-receptors in man, the usual cardiovascular effects commonly associated with other sympathomimetic agents were also observed with terbutaline sulfate.

The pharmacologic effects of beta-adrenergic agonists, including terbutaline, are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic 3’, 5’-adenosine monophosphate (cAMP). Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

Controlled clinical studies have shown that terbutaline sulfate relieves bronchospasm in chronic obstructive pulmonary disease by significantly increasing pulmonary function (e.g., an increase of 15% or more in FEV1 and in FEF25%-75%). After administration of terbutaline sulfate tablets, a measurable change in flow rate usually occurs within 30 minutes, and a clinically significant improvement in pulmonary function occurs within 60 to 120 minutes. The maximum effect usually occurs within 120 to 180 minutes. Terbutaline sulfate also produces a clinically significant decrease in airway and pulmonary resistance, which persists for 4 hours or longer. Significant bronchodilator action (as measured by airway resistance, FEF25%-75% or PEFR) has also been demonstrated for up to 8 hours in some studies.

In studies comparing the effectiveness of terbutaline sulfate with that of ephedrine for up to 3 months, both drugs maintained a significant improvement in pulmonary function throughout this period of treatment.
Patients undergo stem cell collection. Patients receive high-dose melphalan IV with or without trastuzumab (Herceptin®). One day later, patients undergo autologous peripheral blood stem cell (PBSC) transplantation. No more than 7 weeks later, patients proceed to course 2. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.
Treatment: intravenous administration of monoclonal anti body anti- IL6R. The dose is 8 mg/kg up to total dose of 800 mg.
Diabetes is a common chronic disease in most parts of the world. Diabetes-related complications are harmful to the human body. There are also fewer studies on the relationship between specific types of diabetes and clinical diseases such as osteoporosis and Hypogonadism. This study aimed to compare the prevalence of hypogonadism and osteoporosis among male patients with latent autoimmune diabetes (LADA), type 1 diabetes (T1DM) and type 2 diabetes (T2DM) and investigate the protective factors for hypogonadism and osteoporosis in these patients. This cross-sectional study evaluated male patients with LADA, T1DM, and T2DM who visited the endocrinology department of Shanghai Tenth People's Hospital for diabetes management. Sex hormones, lipid profiles, sex hormone-binding globulin (SHBG), glycosylated hemoglobin A1c, beta-cell function, uric acid, and osteocalcin were determined in serum samples. Therefor，clarifying the differences in the clinical characteristics of adult men with LADA, T1DM and T2DM will help to further understand the effects of diabetes on bone metabolism and sex hormones.
The experimental group will receive, in addition to the conventional treatment, a physical exercise intervention along 12 weeks, which will consist of complying with the general recommendations for physical activity: 75 minutes weekly of high intensity physical exercise. The therapeutic exercise intervention will be supervised by a physiotherapist and designed in a progressive, structured and personalized way.
A nano-or micro-scale therapeutic agent for use in the treatment of infections in humans or animals is provided. The therapeutic agent includes a micro-and/or nano-particle carrier that is loaded alone or with at least one inert precursor chemical. The carrier encapsulates the one or more precursor chemicals, which after release from the carrier can be activated in situ at the site of infection by the physiological environment to form the antimicrobial agent. Preferably, the precursor chemical forms an oxidative biocide on release, the oxidative biocide being hydrogen peroxide. Preferably, the precursor chemical further comprises an acetyl donor, which upon release reacts with hydrogen peroxide produced by the peroxygen donor to form a mixture of peracetic acid and hydrogen peroxide. The carrier is preferably in the form of micro-and/or nanoparticles manufactured using a Thermally Induced Phase Separation (TIPS) process, for example, the carrier may comprise a biodegradable polymer such as poly (lactic-co-glycolic acid) (PLGA).
Patients receiving placebo. Patients without previous pathology of any kind who have passed the Covid19 and have respiratory, neurological or musculoskeletal sequelae; to those who will be administered placebo (device off, without emitting).
PURPOSE: This study was aimed to build a prediction model to identify high-risk groups for overweight or obesity among Korean men in their 30s and 40s.
METHODS: This study analyzed data from 28,388 men aged 30-40 years, gathered in the 2022 Community Health Survey. Participants were categorized into two groups based on BMI: underweight/normal weight group and overweight/obese group. This study used chi-squared tests and independent t-tests to compare general and health-related characteristics. Moreover, a prediction model was developed using decision tree analysis, and its validity was verified through a split-sample test.
RESULTS: The proportions of participants in the underweight /normal and overweight/obese groups were 50.4% and 49.6%, respectively. The group with the highest overweight/obesity rate at 60.6% had the characteristics of drinking more than 7 cups at a time, being married, and lacking sleep. On the other hand, the group with the lowest overweight or obesity rate (38.7%) had the characteristics of drinking less than 6 cups of alcohol at a time, getting enough sleep, and smoking less than 15 cigarettes.
CONCLUSIONS: The rate of overweight and obesity among Korean males in their 30s and 40s is significantly high. This study found that individuals who consume more than seven glasses of alcohol at a time, are married, and do not get enough sleep are at high risk of being overweight or obese. Therefore, it is essential to develop and implement targeted intervention programs for this high-risk group of Korean men in their 30s and 40s.
PURPOSE: Despite the increasing preference for minimally invasive surgery for colorectal cancer (CRC), the incidence of prolonged postoperative ileus (PPOI) remains high. Thus, this study aimed to identify risk factors for PPOI in patients with CRC who underwent minimally invasive surgery (MICRS) and to develop a practical nomogram for predicting individual PPOI risk.
METHODS: A consecutive series of 2368 patients who underwent MICRS between 2013 and 2023 at two tertiary academic centers were retrospectively studied. Using the data from 1895 patients in the training cohort, a multivariable logistic regression model was employed to select significant variables for the construction of a best-fit nomogram. The nomogram was internally and externally validated.
RESULTS: PPOI occurred in 9.5% of patients. Six independent risk factors were identified to construct a nomogram: advanced age (OR 1.055, P = 0.002), male sex (OR 2.914, P = 0.011), age-adjusted Charlson comorbidity index ≥ 6 (OR 2.643, P = 0.025), preoperative sarcopenia (OR 0.857, P = 0.02), preoperative prognostic nutritional index (OR 2.206, P = 0.047), and intraoperative fluid overload (OR 2.227, P = 0.045). The AUCs of the model for predicting PPOI in the training and external validation cohorts were 0.887 and 0.838, respectively. The calibration curves demonstrated excellent consistency between the nomogram-predicted and observed probabilities in both cohorts. Individuals with a total nomogram score of < 197 or ≥ 197 were considered to be at low or high risk for PPOI, respectively.
CONCLUSIONS: The integrated nomogram we developed could provide personalized risk prediction of PPOI after MICRS. This quantification enables surgeons to implement personalized prevention strategies, thereby improving patient outcomes.
PURPOSE: A cosmetic composition is provided to enhance anti-oxidant activity effect, MMP-1 generation suppressive effect, collagen synthesis increase effect and skin anti-wrinkling effect. CONSTITUTION: A cosmetic composition for preventing skin aging includes a compound represented by chemical formula 1 as an active ingredient. The cosmetic composition for skin wrinkle improvement includes the compound represented by the chemical formula 1 as the active ingredient. The cosmetic composition for skin whitening includes the compound of the chemical formula 1 as the active ingredient. A cosmetic composition for anti-inflammation includes the compound of the chemical formula 1 as the active ingredient. The cosmetic composition for anti-biotic includes the compound of the chemical formula 1 as the active ingredient. 0.000001-30 wt% of the compound of the chemical formula 1 is included based on the total weight of the cosmetic composition.
The invention provides a composition containing recombinant human collagen, a freeze-dried material, a preparation method of the freeze-dried material and cosmetics. The composition containing the recombinant human collagen comprises the following raw materials in percentage by mass: 0.1 to 10 percent of mannitol, 0.01 to 3 percent of pullulanase polysaccharide, 0.01 to 1.2 percent of recombinant human collagen, 0.01 to 0.1 percent of mevalonolactone and the balance of water. Lyophilized material, prepared by using the composition containing recombinant human collagen. The preparation method of the freeze-dried material comprises the following steps: and dissolving the active ingredients in the raw materials in water, and freeze-drying to obtain the freeze-dried material. Cosmetic comprising said composition containing recombinant human collagen. The composition, the freeze-dried material and the cosmetics containing the recombinant human collagen have the effects of moisturizing, brightening skin, resisting aging, removing wrinkles, protecting, repairing and the like.
The invention relates to methods and compositions for the treatment of pruritis ani and other perianal disorders. There are currently few treatments for these conditions, many of which have significant side effects. The methods of the invention involve the administration, in a cream or lotion of pregabalin, an anti-epileptic agent that has pain relieving properties. This topical form of pregabalin may also include the addition of other agents such as immunomodulators, antibiotics or agents that enhance wound healing. This method may be useful as a new and safe treatment for pruritis ani, skin conditions and other anorectal disorders. Previous positive clinical experience suggests that this new treatment is promising for these disorders.
Patients with breast cancer who present for initial cardio-oncology consultation. Clinical follow up for 18 months.
The Norwegian hip fracture register prospectively collects data on all hip fracture patients including, among others, time to surgery, type of fracture, type of surgery and American Society of Anesthesiologists (ASA) score. The register also collects quality of life data 4 and 12 months after surgery. Using the unique Norwegian personal identification number the data from the Norwegian hip fracture register will be connected with data from the electronic patient record at Akershus University hospital (AHUS). Fast track surgery for hip fracture patients was introduced at the end of 2013. Mortality and quality of life data will be compared for all hip fracture patients operated at AHUS two years before and two years after this change in standard care. The combined data from the register and the electronic patient records will be used for regression analysis.
PURPOSE:To prepare erythropoietin, by transplanting human erythropoietin-producing cell to a thymoprival nude mouse, treating the transplanted cell with the antiserum and complement to the spleen cell of the nude mouse, and using the obtained established erythropoietin cell. CONSTITUTION:Human erythropoietin-producing cell (e.g. renal cancer cell, hepatic cancer cell, etc.) is transplanted to a thymoprival nude mouse, and the transplanted cell is treated with the antiserum and complement to the spleen cell of the nude mouse. Erythropoietin is produced by using the established erythropoietin-producing cell obtained by the above process. Erythropoietin is expected to be useful as a specific medicine against anemia, especially renal anemia, and as a reagent for the investigation of the mechanism of erythrocyte differentiation. Since a nearly constant amount of erythropoietin can be produced constantly by the use of the above established erythropoietin-producing cell, the process is suitable for the industrial production. The falling-off of the producing cell caused by the fibroblast cells predominating over the objective cells according to the progress of the cultivation, can be prevented because the producing cell is treated with the antibody and the complement.
The method and apparatus automatedly generates various reports for a psychotherapy provider. These reports include Treatment Plans, progress reports, scheduling reports and billing reports. The progress reports include a Progress Note which incorporates various selected data into a report for the insurance company. As much of the data is selected from menus, the resulting report can maintain much patient privacy while being satisfactory to the insurance company. More private information can be stored separately in Expanded Text. A Treatment Plan is generated using the various selected data with respect to subsets of emotional factors, intellectual factors, physical factors, social factors, and spiritual factors. These subsets may be chosen randomly or with some periodic selection.
Chromosomal translocations of the nucleoporin 98 (NUP98) gene are found in acute myeloid leukemia (AML) patients leading to very poor outcomes. The oncogenic activity of NUP98 fusion proteins is dependent on the interaction between Mixed Lineage Leukemia 1 and menin. NUP98-rearranged (NUP98-r) leukemia cells also rely on specific kinases, including CDK6 and/or FLT3, suggesting that simultaneous targeting of these kinases and menin could overcome limited sensitivity to single agents. Here, we found that combinations of menin inhibitor, MI-3454, with kinase inhibitors targeting either CDK6 (Palbociclib) or FLT3 (Gilteritinib) strongly enhance the anti-leukemic effect of menin inhibition in NUP98-r leukemia models. We found strong synergistic effects of both combinations on cell growth, colony formation and differentiation in patient samples with NUP98 translocations. These combinations also markedly augmented anti-leukemic efficacy of menin inhibitor in Patient Derived Xenograft models of NUP98-r leukemia. Despite inhibiting two unrelated kinases, when Palbociclib or Gilteritinib were combined with the menin inhibitor, they affected similar pathways relevant to leukemogenesis, including cell cycle regulation, cell proliferation and differentiation. This study provides strong rationale for clinical translation of the combination of menin and kinase inhibitors as novel treatments for NUP98-r leukemia, supporting the unexplored combinations of epigenetic drugs with kinase inhibitors.
At Week (Wk) 0, all eligible participants will initiate intravenous (IV) induction treatment with ustekinumab (UST) on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg). At Week 8, all participants will receive a 90 milligram (mg) subcutaneous (SC) injection of ustekinumab. At Week 16, participants who do not achieve a Crohn's Disease Activity Index (CDAI) improvement of greater than or equal to (\>=) 70 points versus Week 0 (CDAI 70) will leave the study. Remaining participants will be randomized in a 1:1 ratio to either one of two arms for open label maintenance treatment up to Week 48: the treat to target arm or the routine care arm. From Week 48, participants will continue ustekinumab treatment in the study extension period, up to Week 104. Dosing frequency will be adjusted in the extension period for the participants failing to meet the treatment target.
BACKGROUND: to explore the feasibility and effectiveness of para-split laminotomy in the treatment of lumbar intraspinal tumors.
METHODS: We retrospectively review the clinical data of 15 patients suffering lumbar intraspinal tumors, who underwent tumor resection using the para-split laminotomy, from October 2016 to May 2018. Observation indicators were as follows: (1) surgical and postoperative recovery situations; (2) the neurological function of the spinal cord and the follow-up situations.
RESULTS: Mean blood loss was 95.3 ± 58.2 ml, and the mean duration of the surgical procedure was 176.7 ± 35.2 min. All lumbar intraspinal tumors were resected completely. There were no operative complications. The postoperative CT scans showed no pedicle or vertebral fractures. During the follow-up period of 6-18 months (average 10.8 ± 3.9 months), no tumor recurrence or spinal deformation was found according to the imaging examination. CT 3D reconstructions showed that the split laminae tended to heal. The average preoperative JOA score was 15.5 ± 4.9 and the average postoperative JOA score improved to 24.0 ± 3.5 (average improvement rate 65.9 ± 19.6%).
CONCLUSION: The para-split laminotomy could reduce the damage to the posterior spinal tension band and help to protect the stability of the spine. It is feasible and effective to apply the para-split laminotomy to the operation of a lumbar intraspinal tumor, and this technique may be a promising option when considering surgical methods for some multilevel well-circumscribed intraspinal tumors.
The invention provides a stimulus-responsive lipopeptide delivery system, and a preparation method and application thereof, and belongs to the technical field of medicines. The thornThe shock responsive lipopeptide delivery system is constructed based on amphiphilic lipopeptide molecules. The constructed lipopeptide complex has higher encapsulation rate on small molecules and nucleic acid medicaments and can keep stable in blood circulation. Under the triggering of the acidic and reductive environments of endosomes/lysosomes, the oligohistidine blocks in the lipopeptide molecules are protonated, disulfide bonds are broken, the structure of the complex is damaged, and the rapid synchronous release of small molecules and nucleic acid medicines is initiated. SA-pArg  x  Membrane permeation of blocks and pHis  y  Together, the "proton sponge" effect mediates a highly efficient endosome/lysosome evasion process, thereby achieving efficient cytoplasmic co-delivery of hydrophobic small molecules and nucleic acid drugs. The lipopeptide complex delivery system disclosed by the invention provides a new way for co-delivery of medicines with different physicochemical properties and combined treatment of tumors, and has excellent practical application value.
PURPOSE: The aim of this study was to validate the Patient Reported Outcome Measure (PROM) in the Norwegian Tonsil Surgery Register (NTSR) and to examine whether any improvements to the questionnaire could be useful.
METHODS: This is a prospective, descriptive study. NTSR collects data from patients who undergo tonsil surgery and the intention of the register is to improve the quality of treatment and to contribute to research. The patients answers questions about admission due to postoperative haemorrhage, infection and pain 30 days after surgery. 305 patients were contacted on phone 1-2 weeks after answering the questionnaires electronically (ePROM) and asked the same questions. 180 of 305 patients we contacted had some kind of complications after surgery. They were asked additional questions to search for possible points for improvement of the questionnaire.
RESULTS: When comparing the results on the ePROM with the answers on phone, we found that 12 out of 14 variables achieve almost perfect agreement (AC1 ≥ 0.81). Two variables are categorized to be substantial agreement (AC1 = 0.61-0.80). The additional questions showed us that the questionnaire can be improved with more detailed information regarding the severity of the postoperative haemorrhage and the need of better treatment against postoperative pain.
CONCLUSION: This study shows that the information from the 30-day ePROM has high reliability. The questions were understood as they were intended, and the answers reflect what the patients had of complications. Some changes can be done to improve the questionnaire and to open up for more research around the tonsillectomy procedure.
The invention relates to a preparation method of a Chinese medicinal wine for treating a cough, which, as a most common disease, is a respiratory tract infection caused by bacteria and viruses, and is mostly caused by a cold. However, coughs fall into different types, such as heat cough, cold cough, and cough due to common cold, etc. Thus, the traditional Chinese medicine is also divided into hot, cool and tepid. Some patients cannot find the right remedy for an illness, so a treatment effect cannot be reached. Directed at various coughs, i.e. heat cough, cold cough, and cough due to common cold, the Chinese medicinal wine of the invention can have a good effect.
PURPOSE:A liquid food causing no disorder such as diarrhea, etc., by oral admin istration or by administration through a tube, comprising a nutritive substance and an extract of tea leaf or an extract of coffee beans. CONSTITUTION:A nutritive substance (e.g., edible fat and oil raw material, soybean oil, rice oil, beef tallow, lard, etc.; protein raw material, soybean protein, wheat protein, milk, the york of an egg, meat extract, etc.) is emulsified or blended with an extract of tea leaf (e.g., solution obtained by extacting refined green tea, powdered green tea, green tea of middle grade, toasted tea, etc. with water, etc.) or an extract of coffee beans, to give a fluid food. An amount of the extract added is preferably 0.05-0.2wt% solid content of the extract except water in the final liquid food. The liquid food is adjusted to preferably 6.0-7pH. The fluid food is not coagulated even if it is sterilized under heating, nor even if packed into a can, etc., and sterilized under heating, so that a liquid food with high shelf stability is obtained.